Physician profile
Johnathan Fagg
NPI 1811427636
$1,344.22
in general payments reported to CMS, 2019-2025
12 companies · $620 in 2025
The $620 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2023: $239 · 2024: $375 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $772 · Travel and Lodging: $368 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $772.32 |
| Travel and Lodging | $367.66 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $367.66 | 2025 | Illumisite |
| United Therapeutics Corporation | $216.10 | 2023-2024 | Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $140.95 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $109.85 | 2024 | Tezspire |
| Janssen Pharmaceuticals, INC | $109.25 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $94.99 | 2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $85.81 | 2024 | Winrevair |
| Baxter Healthcare | $81.08 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Ani Pharmaceuticals, INC. | $61.00 | 2024-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $32.84 | 2025 | Nucala, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.46 | 2024 | Ofev |
| Pulmonx Corporation | $14.23 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnathan Fagg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.